Quitting Matters Human Immunodeficiency Virus Hybrid Trial
Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Mar 12, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Tobacco use has alarmingly high rates among people with Human Immunodeficiency Virus (HIV) (PWH), 43% compared with 15% in the general population. Due to the development of highly effective treatments for HIV and the resulting increased longevity among PWH, this population now loses more life years to smoking than to HIV infection itself. Novel and effective models to deliver wider reaching smoking cessation interventions for PWH are highly needed and indicated as a priority for National Institute of Health. Digital therapeutics (DTx) may be a novel, scalable, and highly available approach ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Self-reported daily cigarette smoking over the past 30 days
- • 2. Self-reported HIV status
- • 3. Age 18 or older
- • 4. Desire to quit smoking
- • 5. Willing and medically eligible to use NRT
- • 6. Currently receiving HIV care
- • 7. Currently owning an Android or iOS smartphone
- Exclusion Criteria:
- • 1. Current acute psychotic episode or unsafe to participate in the study
- • 2. Pregnant or intending to become pregnant in the next 6 months
- • 3. Currently receiving any pharmacological and/or behavioral intervention or counseling for smoking cessation
- • 4. Any medical condition or medication that could compromise subject safety, as determined by the PIs and/or study physician
- • 5. Not able to fluently speak and write in English
- • 6. Hearing, comprehension, visual, speech, or motor limitations that preclude study participation
Trial Officials
Roger Vilardaga Viera, Ph.D.
Principal Investigator
Wake Forest University Health Sciences
About Wake Forest University Health Sciences
Wake Forest University Health Sciences is a leading academic research institution dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on multidisciplinary collaboration, the organization leverages its extensive expertise in medical research, patient care, and education to develop and evaluate new therapies and interventions. Committed to improving patient outcomes and public health, Wake Forest University Health Sciences fosters a dynamic environment for scientific inquiry, engaging in a wide range of clinical studies that address pressing health challenges. Through its rigorous methodologies and ethical standards, the institution aims to contribute significantly to the medical field and enhance the quality of life for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported